ÃâÇ÷¼º Áúȯ Ä¡·á ½ÃÀå º¸°í¼ : À¯Çüº°, ¾à¹° Á¾·ùº°, À¯Åë ä³Îº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)
Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2025-2033
»óǰÄÚµå
:
1753906
¸®¼Ä¡»ç
:
IMARC Group
¹ßÇàÀÏ
:
2025³â 06¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 146 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è ÃâÇ÷¼º Áúȯ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2024³â 158¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀå ±Ô¸ð°¡ 248¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 4.87%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.
ÃâÇ÷¼º Áúȯ¿¡´Â Ç÷¿ìº´ A¿Í B, Æù ºô·¹ºê¶õÆ®º´, Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º Àڹݺ´(ITP), ºñŸ¹Î K¿Í ÀÎÀÚ II, V, VII, X, XIIÀÇ °áÇÌÀÌ Æ÷ÇԵ˴ϴÙ. À̵é ÁúȯÀº Ç÷¾× ÀÀ°í °úÁ¤À» ¾ïÁ¦ÇÏ´Â Áúȯ±ºÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº ¶ÇÇÑ ºÎ»ó ÈÄ ´Ù·®ÀÇ Àå±â°£ ÃâÇ÷À» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿ù°æ ½Ã ÃâÇ÷ÀÌ ¸¹°í, ¸ÛÀÌ Àß µé°í, ÄÚÇǰ¡ Àß ³ª°í, °¡º¿î »óó·Î ÀÎÇÑ ÃâÇ÷ÀÌ ¸¹°í, °üÀý¿¡¼ ÃâÇ÷ÀÌ ¸¹Àº µîÀÇ Áõ»óÀÌ ÀÖ½À´Ï´Ù. ÀüÇ÷±¸°è»ê(CBC), Ç÷¼ÒÆÇ ÀÀÁý·Â, ÃâÇ÷½Ã°£ µîÀÇ Ç÷¾×°Ë»ç¸¦ ÅëÇØ Áø´ÜÇÕ´Ï´Ù. Ä¡·á¿¡´Â ¾Æµå·¹³ëÅ©·Ò ¸ð³ë¼¼¹ÌÄ®¹ÙÁ¸, ¸Á¸·ÃâÇ÷, ºñÃâÇ÷, ¾Æ¹Ì³ëÄ«ÇÁ·Î»ê, ¾ÆÇÁ·ÎƼ´Ñ, öºÐÁ¦ µîÀÇ ¾à¹°ÀÌ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ ¾àÁ¦µéÀº ƯÁ¤ Áõ»óÀ» ÃÖ¼ÒÈÇϰí ȯÀÚÀÇ »ý¸í ¿¬Àå¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ÃâÇ÷¼º Áúȯ Ä¡·á¿¡´Â ¼öÇ÷, º¸Ãæ¿ä¹ý, ÀÀ°íÀÎÀÚ ¹× Ç÷Àå Áֻ絵 Æ÷ÇԵ˴ϴÙ.
ÃâÇ÷¼º Áúȯ Ä¡·áÁ¦ ½ÃÀå µ¿Çâ:
´ëÁßÀÇ ÃâÇ÷¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÀÌ·¯ÇÑ Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â Àü ¼¼°è ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ÃâÇ÷¼º Áúȯ Ä¡·á¿¡ ´ëÇÑ °æÁ¦Àû Áö¿øÀ» Á¦°øÇϰí ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÏ´Â °Ç° º¸ÇèÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¹Àº ±¹°¡ÀÇ Á¤ºÎ ±â°üÀÌ ÇåÇ÷°ú Ç÷Àå ±âÁõ¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇåÇ÷ Ä·ÇÁ¸¦ Àå·ÁÇϱâ À§ÇÑ ³ë·Âµµ Çϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, È¿°úÀûÀÎ ´ëü Ä¡·á¹ýÀÌ ÀÖ´Ù´Â ÀνÄÀÌ È®»êµÇ°í ÀÖ´Â °Íµµ ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸°³¹ß(R&D) Ȱµ¿°ú ÇコÄɾî ÀÎÇÁ¶ó ¹× Áø´Ü ±â¼úÀÇ ´ëÆøÀûÀÎ °³¼±µµ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ Àü¸ÁÀ» °¡Á®´Ù ÁÙ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®
- ¼¼°è ÃâÇ÷¼º Áúȯ Ä¡·áÁ¦ ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô º¯ÈÇØ¿Ô°í, ¾ÕÀ¸·Î ¾î¶»°Ô º¯ÈÇÒ °ÍÀΰ¡?
- COVID-19°¡ ¼¼°è ÃâÇ÷¼º Áúȯ Ä¡·áÁ¦ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
- ÁÖ¿ä Áö¿ª ½ÃÀåÀ̶õ?
- À¯Çüº° ½ÃÀå ºÐ¼®Àº?
- ¾àÁ¦ Á¾·ùº° ½ÃÀå ÇöȲÀº?
- ÆÇ¸Å ä³Îº° ½ÃÀå ÇöȲÀº?
- ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº ¾î¶»°Ô µÇ´Â°¡?
- »ê¾÷ °¡Ä¡»ç½½ÀÇ ´Ù¾çÇÑ ´Ü°è´Â ¹«¾ùÀΰ¡?
- ¾÷°èÀÇ ÁÖ¿ä ÃËÁø¿äÀΰú °úÁ¦´Â ¹«¾ùÀΰ¡?
- ¼¼°è ÃâÇ÷¼º Áúȯ Ä¡·áÁ¦ ½ÃÀå ±¸Á¶¿Í ÁÖ¿ä ±â¾÷Àº?
- ¾÷°è ³» °æÀïÀº ¾î´À Á¤µµÀΰ¡?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»ç ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ¼Ò°³
Á¦5Àå ¼¼°èÀÇ ÃâÇ÷¼º Áúȯ Ä¡·á ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°
- Ç÷¿ìº´ A
- Ç÷¿ìº´ B
- Æùºô·¹ºê¶õÆ®º´
- ±âŸ
Á¦7Àå ½ÃÀå ³»¿ª : ¾à¹° Á¾·ùº°
- Ç÷Àå À¯·¡ ÀÀ°íÀÎÀÚ ³óÃ๰
- ÁÖ¿ä ºÎ¹®
- Á¦VIII ÀÎÀÚ
- Á¦IXÀÎÀÚ
- Æùºô·¹ºê¶õÆ®º´ ÀÎÀÚ
- Ȱ¼ºÈ ÇÁ·ÎÆ®·Òºó º¹ÇÕü ³óÃ๰
- ÀçÁ¶ÇÕ ÀÀ°íÀÎÀÚ ³óÃ๰
- ÁÖ¿ä ºÎ¹®
- Á¦VIII ÀÎÀÚ
- Æùºô·¹ºê¶õÆ®º´ ÀÎÀÚ
- Á¦IXÀÎÀÚ
- µ¥½º¸ðÇÁ·¹½Å
- Ç×¼¶À¯¼Ò¿ëÇØÁ¦
- ÇǺ기 ½Ç¶õÆ®
- ±âŸ
Á¦8Àå ½ÃÀå ³»¿ª : À¯Åë ä³Îº°
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ½ºÅä¾î
Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°
Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦11Àå SWOT ºÐ¼®
Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦13Àå Porter's Five Forces ºÐ¼®
- °³¿ä
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- °æÀï Á¤µµ
- ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦14Àå °¡°Ý ºÐ¼®
Á¦15Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ °³¿ä
- AbbVie Inc
- Alnylam Pharmaceuticals Inc.
- Bayer AG
- CSL Behring(CSL Limited)
- Grifols S.A.
- Johnson & Johnson
- Novo Nordisk A/S
- Octapharma AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Wellona Pharma
ksm
¿µ¹® ¸ñÂ÷
The global bleeding disorders treatment market size reached USD 15.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 24.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.87% during 2025-2033.
Bleeding disorders involve hemophilia A and B, Von Willebrand disease, idiopathic thrombocytopenic purpura (ITP), and deficiencies of vitamin K and factors II, V, VII, X, and XII. They are a class of conditions that disrupt the blood clotting process in an individual. They can also lead to heavy and prolonged bleeding after an injury. They have symptoms, including heavy menstrual bleeding, easy bruising, frequent nosebleeds, excessive bleeding from minor cuts, and joint bleeding. They are diagnosed through blood tests of complete blood count (CBC), platelet aggregation, and bleeding time. Their treatment comprises medications, including adrenochrome monosemicarbazone, retinal hemorrhage, epistaxis, aminocaproic acid, aprotinin, and iron supplements. These medications can aid in minimizing specific symptoms and prolonging the life of patients. Bleeding disorders treatment also includes blood transfusion, replacement therapy, and injections of a clotting factor and plasma.
Bleeding Disorders Treatment Market Trends:
The increasing prevalence of bleeding disorders among the masses and the rising geriatric population, which is more susceptible to these medical conditions, are among the key factors driving the market around the world. Moreover, the growing adoption of health insurance policies that provide financial assistance for bleeding disorders treatment and reduce healthcare expenses is influencing the market positively. In addition, governing agencies of numerous countries are generating awareness about blood and plasma donation. They are also undertaking initiatives to promote blood donation camps. Apart from this, the increasing awareness about the availability of effective treatment alternatives is creating a positive outlook for the market. Furthermore, research and development (R&D) activities and considerable improvements in the healthcare infrastructure and diagnostic technologies are expected to provide a favorable outlook to the market.
Key Market Segmentation:
Breakup by Type:
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
Breakup by Drug Class:
- Plasma-derived Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Factor for Von Willebrand Disease
- Activated Prothrombin Complex Concentrate
- Recombinant Coagulation Factor Concentrates
- Factor VIII
- Factor for Von Willebrand Disease
- Factor IX
- Desmopressin
- Antifibrinolytics
- Fibrin Sealants
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
Breakup by End User:
- Hospitals
- Clinics
- Academic and Research Institutes
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc, Alnylam Pharmaceuticals Inc., Bayer AG, CSL Behring (CSL Limited), Grifols S.A., Johnson & Johnson, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Wellona Pharma.
Key Questions Answered in This Report:
- How has the global bleeding disorders treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global bleeding disorders treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the distribution channel?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global bleeding disorders treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Bleeding Disorders Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Hemophilia A
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Hemophilia B
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Von Willebrand Disease
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Drug Class
- 7.1 Plasma-derived Coagulation Factor Concentrates
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Factor VIII
- 7.1.2.2 Factor IX
- 7.1.2.3 Factor for Von Willebrand Disease
- 7.1.2.4 Activated Prothrombin Complex Concentrate
- 7.1.3 Market Forecast
- 7.2 Recombinant Coagulation Factor Concentrates
- 7.2.1 Market Trends
- 7.2.2 Key Segments
- 7.2.2.1 Factor VIII
- 7.2.2.2 Factor for Von Willebrand Disease
- 7.2.2.3 Factor IX
- 7.2.3 Market Forecast
- 7.3 Desmopressin
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Antifibrinolytics
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Fibrin Sealants
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Clinics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Academic and Research Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 AbbVie Inc
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Alnylam Pharmaceuticals Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Bayer AG
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 CSL Behring (CSL Limited)
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.5 Grifols S.A.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Johnson & Johnson
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Novo Nordisk A/S
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Octapharma AG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 SWOT Analysis
- 15.3.9 Pfizer Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Takeda Pharmaceutical Company Limited
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Wellona Pharma
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
°ü·ÃÀÚ·á